AnchorDx announced today that it enrolled the first patient in its UriFind bladder cancer assay clinical trial in the U.S. Guangzhou, China-based AnchorDx’s multi-center, prospective trial includes more than 1,000 patients. It tests the non-invasive, quantitative real-time PCR assay in targeted patients. AnchorDx expects the trial to include about 10 sites of urology clinics and […]